Safety of Monoclonal Antibodies in Children Affected by SARS-CoV-2 Infection

Monoclonal antibody therapies for COVID-19 have been frequently used in adults, whereas there are little data regarding the safety or efficacy of monoclonal antibody treatments in pediatric patients affected by COVID-19. We report our experience in the administration of mAb as a treatment for SARS-C...

Descripción completa

Detalles Bibliográficos
Autores principales: Romani, Lorenza, Calò Carducci, Francesca Ippolita, Chiurchiù, Sara, Cursi, Laura, De Luca, Maia, Di Giuseppe, Martina, Krzysztofiak, Andrzej, Lancella, Laura, Palma, Paolo, Vallesi, Leonardo, Corsetti, Tiziana, Campana, Andrea, Nicastri, Emanuele, Rossi, Paolo, Bernardi, Stefania
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947030/
https://www.ncbi.nlm.nih.gov/pubmed/35327741
http://dx.doi.org/10.3390/children9030369
Descripción
Sumario:Monoclonal antibody therapies for COVID-19 have been frequently used in adults, whereas there are little data regarding the safety or efficacy of monoclonal antibody treatments in pediatric patients affected by COVID-19. We report our experience in the administration of mAb as a treatment for SARS-CoV-2 infection in children aged from 24 days to 18 years old.

Ejemplares similares